Payment overview · 2025
General Payments
$398.61
19 reported records · 11 companies
Healthcare provider profile · identity verified
Jack D Anderson, DO
Allopathic & Osteopathic Physicians|Family Medicine · TOMPKINSVILLE, KY · NPI 1245527969
Verified facts
What the public records show
CMS Open Payments records show Jack D Anderson, DO received $398.61 in general payments during 2025 across 19 reported records.
ABBVIE INC. accounted for 36.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $146.24 | 36.7% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $69.18 | 17.4% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $36.17 | 9.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.48 | 7.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.57 | 4.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.37 | 4.6% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $18.05 | 4.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.93 | 4.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.27 | 3.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.84 | 3.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.51 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $398.61 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $146.24 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $69.18 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $36.31 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $36.17 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $32.87 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.48 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 111 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 64 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
64 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
111 | 15 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 481 | 107 |
| Gabapentin | Gabapentin | 336 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 319 | 53 |
| Furosemide | Furosemide | 303 | 67 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 267 | 59 |
| Omeprazole | Omeprazole | 264 | 62 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 250 | 29 |
| Potassium Chloride | Potassium Chloride | 234 | 64 |
| Lisinopril | Lisinopril | 231 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 210 | 43 |
| Metformin Hcl | Metformin Hcl | 189 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 169 | 37 |
| Clonazepam | Clonazepam | 161 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 159 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 158 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 157 | 29 |
| Atenolol | Atenolol | 154 | 27 |
| Azithromycin | Azithromycin | 141 | 95 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 129 | 49 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 126 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 125 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 119 | 25 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 118 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 23 |
| Buspirone Hcl | Buspirone Hcl | 116 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 33 |
| Ibuprofen | Ibuprofen | 113 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 113 | 37 |
| Eliquis | Apixaban | 111 | 15 |
| Alprazolam | Alprazolam | 109 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 32 |
| Meloxicam | Meloxicam | 105 | 24 |
| Montelukast Sodium | Montelukast Sodium | 100 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 96 | 20 |
| Diazepam | Diazepam | 96 | 12 |
| Losartan Potassium | Losartan Potassium | 95 | 20 |
| Promethazine Hcl | Promethazine Hcl | 93 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 86 | 30 |
| Trazodone Hcl | Trazodone Hcl | 84 | 13 |
| Tramadol Hcl | Tramadol Hcl | 80 | 14 |
| Spironolactone | Spironolactone | 77 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 75 | 24 |
| Mirtazapine | Mirtazapine | 75 | 14 |
| Ozempic | Semaglutide | 68 | 14 |
| Ondansetron Odt | Ondansetron | 67 | 22 |
| Sertraline Hcl | Sertraline Hcl | 67 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 65 | suppressed |
| Carvedilol | Carvedilol | 64 | 11 |
| Lorazepam | Lorazepam | 64 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 17 |
| Methylprednisolone | Methylprednisolone | 59 | 46 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 12 |
| Prednisone | Prednisone | 57 | 35 |
| Allopurinol | Allopurinol | 56 | 13 |
| Celecoxib | Celecoxib | 56 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 56 | 45 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | suppressed |
| Finasteride | Finasteride | 49 | suppressed |
| Linzess | Linaclotide | 49 | 13 |
| Simvastatin | Simvastatin | 49 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 13 |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 45 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 45 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 38 |
| Ezetimibe | Ezetimibe | 44 | suppressed |
| Valsartan | Valsartan | 44 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 43 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 42 | 13 |
| Meclizine Hcl | Meclizine Hcl | 42 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 42 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Bumetanide | Bumetanide | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Glimepiride | Glimepiride | 39 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 35 |
| Glipizide | Glipizide | 37 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Nystatin | Nystatin | 33 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Famotidine | Famotidine | 31 | suppressed |
| Mupirocin | Mupirocin | 30 | 21 |
| Nitroglycerin | Nitroglycerin | 30 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 21 |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 22 |
| Topiramate | Topiramate | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 26 | 11 |
| Metronidazole | Metronidazole | 26 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 26 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 25 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Lacosamide | Lacosamide | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Vraylar | Cariprazine Hcl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Zonisamide | Zonisamide | 17 | suppressed |
| Indomethacin | Indomethacin | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 14 |
| Temazepam | Temazepam | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Metaxalone | Metaxalone | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $398.61 · 19 records | ABBVIE INC. | Cologuard Collection Kit, ELIQUIS, Korlym, MOUNJARO, NURTEC ODT, SUBLOCADE, TRELEGY ELLIPTA, TRINTELLIX, VOQUEZNA, VRAYLAR, XIFAXAN, ZAVZPRET, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error